The AB/BA crossover: past, present and future?

The AB/BA design is reviewed from a historical perspective. Particular attention is paid to the problem of carry-over and various attempts to deal with it. The two-stage procedure, an approach which was popular for many years, is shown to be unsafe. The analysis of AB/BA designs with baseline data is also considered. It is shown that such baselines do not provide a cure for the problem of carry-over; and it is concluded that any rational analysis of such trials will always be dependent on assumptions regarding carry-over, and that it is necessary to pay particular attention to washout periods. Under such circumstances analysis of covariance may be useful. In conclusion, some speculative comments about future lines of research are offered.

[1]  A. Willan,et al.  Using baseline measurements in the two-period crossover clinical trial. , 1986, Controlled clinical trials.

[2]  E. C. Fieller.  The Biological Standardization of Insulin , 1940 .

[3]  S Senn,et al.  The first t-test. , 1994, Statistics in medicine.

[4]  Cleophas Tj.  The performance of the two-stage analysis of two-treatment, two-period crossover trials. , 1991 .

[5]  A P Grieve,et al.  Extending a Bayesian analysis of the two-period crossover to allow for baseline measurements. , 1994, Statistics in medicine.

[6]  J. Chassan.  199. Note: On the Analysis of Simple Cross-Overs with Unequal Numbers of Replicates , 1964 .

[7]  M. Palmqvist,et al.  Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beta 2-agonist. , 1992, The Journal of allergy and clinical immunology.

[8]  Student,et al.  THE PROBABLE ERROR OF A MEAN , 1908 .

[9]  John Barrett,et al.  Book Reviews , 1821, Heredity.

[10]  M. Kenward,et al.  Design and Analysis of Cross-Over Trials , 1989 .

[11]  A. Grieve.  A Note on the Analysis of the Two-Period Crossover Design When the Period-Treatment Interaction is Significant , 1987 .

[12]  S. Senn.  Problems with the two stage analysis of crossover trials. , 1991, British journal of clinical pharmacology.

[13]  S J Senn,et al.  Is the 'simple carry-over' model useful? , 1992, Statistics in medicine.

[14]  H. Zimmermann,et al.  Model building and testing for the change‐over design , 1980 .

[15]  J. Chassan.  A note on relative efficiency in clinical trials. , 1970, The Journal of clinical pharmacology and the journal of new drugs.

[16]  David Birkes,et al.  Alternative Methods of Regression: Birkes/Alternative , 1993 .

[17]  A. Grieve.  The two-period changeover design in clinical trials. , 1982, Biometrics.

[18]  E. M. Chi.  Analysis of Cross‐Over Trials When Within‐Subject Errors Follow an AR(1) Process , 1992 .

[19]  The action of optical isomers: II. Hyoscines. , The Journal of physiology.

[20]  J. Poloniecki,et al.  The Two Period Cross Over Trial , 1982 .

[21]  A. Cushny,et al.  The action of optical isomers , 1905 .

[22]  A. Willan,et al.  Using the maximum test statistic in the two-period crossover clinical trial. , 1988, Biometrics.

[23]  N. Chilton,et al.  Crossover designs involving two treatments. , 1974, Journal of periodontal research. Supplement.

[24]  M. Hills,et al.  The Two‐Period Crossover Trial , 1982 .

[25]  G G Koch,et al.  The use of non-parametric methods in the statistical analysis of the two-period change-over design. , 1972, Biometrics.

[26]  Marc A. Evans,et al.  Cross-Over Experiments: Design, Analysis and Application , 1992 .

[27]  S. Senn.  Cross-over trials, carry-over effects and the art of self-delusion. , 1988, Statistics in medicine.

[28]  J. Poloniecki,et al.  Further Analysis of the Hills and Armitage Enuresis Data , 1981 .

[29]  A. Willan,et al.  Carryover and the two-period crossover clinical trial. , 1986, Biometrics.

[30]  D. Hauschke,et al.  International Harmonization of Regulatory Bioequivalence Requirements , 1993 .

[31]  S. Senn,et al.  The use of baselines in clinical trials of bronchodilators. , 1989, Statistics in medicine.

[32]  S. Senn.  Suspended judgment n-of-1 trials. , 1993, Controlled clinical trials.

[33]  P. Freeman.  The performance of the two-stage analysis of two-treatment, two-period crossover trials. , 1989, Statistics in medicine.

[34]  B. W. Brown.  The crossover experiment for clinical trials. , 1980, Biometrics.

[35]  W. Lehmacher,et al.  Analysis of the crossover design in the presence of residual effects. , 1991, Statistics in medicine.

[36]  Stephen Senn,et al.  Cross-over trials in clinical research , 1993 .

[37]  S. Dubey.  Current Thoughts on Crossover Designs , 1986 .

[38]  M. Kenward,et al.  The analysis of data from 2 x 2 cross-over trials with baseline measurements. , 1987, Statistics in medicine.

[39]  A. Rossier.  Letter to the Editor , 1986, Paraplegia.

[40]  D. Preece.  T is for Trouble (And Textbooks): A Critique of Some Examples of the Paired‐Samples T‐Test , 1982 .

[41]  A P Grieve,et al.  A Bayesian analysis of the two-period crossover design for clinical trials. , 1985, Biometrics.

[42]  J. Matthews.  Cross‐over. Trials in clinical research. Stephen Senn, Wiley, Chichester, 1993. no. of pages pages: XV + 266. price: £24.95. ISBN 0‐471‐93493‐3 , 1994 .

[43]  H. I. Patel.  Use of baseline measurements in the two-period crossover design , 1983 .

[44]  M. Hills,et al.  The two-period cross-over clinical trial. , 1979, British journal of clinical pharmacology.

[45]  J. Fleiss,et al.  A critique of recent research on the two-treatment crossover design. , 1989, Controlled clinical trials.

[46]  Fleiss Jl,et al.  On multiperiod crossover studies. , 1986 .